Natural Product Modulators to Overcome Multidrug Resistance In Cancer

REFERENCES

• Persidis A: Cancer multidrug resistance. Nat Biotechnol 17, 94–95, 1999.
   PubMed Web of Science ®Google Scholar
• Baguley BC: Multidrug resistance in cancer. Methods Mol Biol 596, 1–14, 2010.
   PubMedGoogle Scholar
• Schinkel AH and Jonker JW: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55, 3–29, 2003.
   PubMed Web of Science ®Google Scholar
• Wu CP, Ohnuma S, and Ambudkar SV: Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 12, 609–620, 2011.
   PubMed Web of Science ®Google Scholar
• Dean M, Hamon Y, Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42, 1007–1017, 2001.
   PubMed Web of Science ®Google Scholar
• Sharom FJ: The P-glycoprotein multidrug transporter. Essays Biochem 50, 161–178, 2011.
   PubMed Web of Science ®Google Scholar
• Beaulieu E, Demeule M, Ghitescu L, and Beliveau R: P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 326 (Pt 2), 539–544, 1997.
   PubMed Web of Science ®Google Scholar
• Amin ML: P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7, 27–34, 2013.
   PubMedGoogle Scholar
• Sun J, He ZG, Cheng G, Wang SJ, Hao XH, et al.: Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 10, RA5–R14, 2004.
   Web of Science ®Google Scholar
• Martins A, Vasas A, Schelz Z, Viveiros M, Molnar J, et al.: Constituents of Carpobrotus edulis inhibit P-glycoprotein of MDR1-transfected mouse lymphoma cells. Anticancer Res 30, 829–835, 2010.
   PubMed Web of Science ®Google Scholar
• Hipfner DR, Almquist KC, Leslie EM, Gerlach JH, Grant CE, et al.: Membrane topology of the multidrug resistance protein (MRP). A study of glycosylation-site mutants reveals an extracytosolic NH2 terminus. J Biol Chem 272, 23623–23630, 1997.
   PubMed Web of Science ®Google Scholar
• Hipfner DR, Deeley RG, and Cole SP: Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1461, 359–376, 1999.
   Google Scholar
• Renes J, de Vries EG, Nienhuis EF, Jansen PL, and Muller M: ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol 126, 681–688, 1999.
   PubMed Web of Science ®Google Scholar
• Bagrij T, Klokouzas A, Hladky SB, and Barrand MA: Influences of glutathione on anionic substrate efflux in tumour cells expressing the multidrug resistance-associated protein, MRP1. Biochem Pharmacol 62, 199–206, 2001.
   PubMed Web of Science ®Google Scholar
• Zaman GJ, Lankelma J, van Tellingen O, Beijnen J, Dekker H, et al.: Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci U S A 92, 7690–7694, 1995.
   PubMed Web of Science ®Google Scholar
• Akan I, Akan S, Akca H, Savas B, and Ozben T: Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine sulfoximine. Cancer Cell Int 5, 22, 2005.
   PubMed Web of Science ®Google Scholar
• Muller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, et al.: Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A 91, 13033–13037, 1994.
   PubMed Web of Science ®Google Scholar
• Kearns PR and Hall AG: Microtiter plate technique for the measurement of glutathione in fresh and cryopreserved lymphoblasts using the enzyme recycling method. Methods Mol Med 28, 83–90, 1999.
   PubMedGoogle Scholar
• Loe DW, Almquist KC, Deeley RG, and Cole SP: Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 271, 9675–9682, 1996.
   PubMed Web of Science ®Google Scholar
• Loe DW, Deeley RG, and Cole SP: Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res 58, 5130–5136, 1998.
   PubMed Web of Science ®Google Scholar
• Yan CY, Ferrari G, and Greene LA: N-acetylcysteine-promoted survival of PC12 cells is glutathione-independent but transcription-dependent. J Biol Chem 270, 26827–26832, 1995.
   PubMed Web of Science ®Google Scholar
• Loe DW, Deeley RG, and Cole SP: Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). J Pharmacol Exp Ther 293, 530–538, 2000.
   PubMed Web of Science ®Google Scholar
• Leslie EM, Mao Q, Oleschuk CJ, Deeley RG, and Cole SP: Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. Mol Pharmacol 59, 1171–1180, 2001.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy P and Schuetz JD: Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 46, 381–410, 2006.
   PubMed Web of Science ®Google Scholar
• Cervenak J, Andrikovics H, Ozvegy-Laczka C, Tordai A, Nemet K, et al.: The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology. Cancer Lett 234, 62–72, 2006.
   PubMed Web of Science ®Google Scholar
• Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, et al.: The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 99, 15649–15654, 2002.
   PubMed Web of Science ®Google Scholar
• van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, et al.: The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine. Cancer Res; 63, 6447–6452, 2003.
   PubMed Web of Science ®Google Scholar
• Kellen JA: The reversal of multidrug resistance: an update. J Exp Ther Oncol 3, 5–13, 2003.
   PubMedGoogle Scholar
• Ullah MF: Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev 9, 1–6, 2008.
   PubMed Web of Science ®Google Scholar
• Yang K, Wu J, and Li X: Recent advances in the research of P-glycoprotein inhibitors. Biosci Trends 2, 137–146, 2008.
   PubMed Web of Science ®Google Scholar
• He SM, Li R, Kanwar JR, and Zhou SF: Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Curr Med Chem 18, 439–481, 2011.
   PubMed Web of Science ®Google Scholar
• Ferry DR, Traunecker H, and Kerr DJ: Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A, 1070–1081, 1996.
   PubMed Web of Science ®Google Scholar
• Thomas H and Coley HM: Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10, 159–165, 2003.
   PubMedGoogle Scholar
• Robert J and Jarry C: Multidrug resistance reversal agents. J Med Chem 46, 4805–4817, 2003.
   PubMed Web of Science ®Google Scholar
• Ozben T: Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 580, 2903–2909, 2006.
   PubMed Web of Science ®Google Scholar
• Bogush TA, Zabotina TN, Bogush EA, Chmutin EF, Komov DV, et al.: New approach to vital analysis of functional activity in ABC transporters (markers for multidrug resistance) in solid tumors by the method of flow cytofluorometry. Bull Exp Biol Med 135, 482–488, 2003.
   PubMed Web of Science ®Google Scholar
• Twentyman PR and Bleehen NM: Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer; 27, 1639–1642, 1991.
   PubMed Web of Science ®Google Scholar
• Krishna R and Mayer LD: Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11, 265–283, 2000.
   PubMed Web of Science ®Google Scholar
• Bohme M, Buchler M, Muller M, and Keppler D: Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 333, 193–196, 1993.
   PubMed Web of Science ®Google Scholar
• Song S, Suzuki H, Kawai R, Tanaka C, Akasaka I, et al.: Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats. Drug Metab Dispos 26, 1128–1133, 1998.
   PubMed Web of Science ®Google Scholar
• Lhomme C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, et al.: Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 26, 2674–2682, 2008.
   PubMed Web of Science ®Google Scholar
• Saraswathy M and Gong S: Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv 31, 1397–1407, 2013.
   PubMed Web of Science ®Google Scholar
• Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, et al.: P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59, 3944–3948, 1999.
   PubMed Web of Science ®Google Scholar
• Bates S, Kang M, Meadows B, Bakke S, Choyke P, et al.: A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Cancer 92, 1577–1590, 2001.
   PubMed Web of Science ®Google Scholar
• Fischer V, Rodriguez-Gascon A, Heitz F, Tynes R, Hauck C, et al.: The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 26, 802–811, 1998.
   PubMed Web of Science ®Google Scholar
• Kang MH, Figg WD, Ando Y, Blagosklonny MV, Liewehr D, et al.: The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin Cancer Res 7, 1610–1617, 2001.
   PubMed Web of Science ®Google Scholar
• Liscovitch M and Lavie Y: Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5, 349–355, 2002.
   PubMedGoogle Scholar
• Mayur YC, Peters GJ, Prasad VV, Lemo C, and Sathish NK: Design of new drug molecules to be used in reversing multidrug resistance in cancer cells. Curr Cancer Drug Targets 9, 298–306, 2009.
   PubMed Web of Science ®Google Scholar
• Martelli C, Alderighi D, Coronnello M, Dei S, Frosini M, et al.: N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors. J Med Chem 52, 807–817, 2009.
   PubMed Web of Science ®Google Scholar
• Martelli C, Coronnello M, Dei S, Manetti D, Orlandi F, et al.: Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors. J Med Chem 53, 1755–1762, 2010.
   PubMed Web of Science ®Google Scholar
• Lee CH: Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR). Curr Med Chem Anticancer Agents 4, 43–52, 2004.
   PubMedGoogle Scholar
• Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, et al.: Discovery and characterization of OC144–093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 60, 2964–2972, 2000.
   PubMed Web of Science ®Google Scholar
• Nobili S, Landini I, Giglioni B, and Mini E: Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7, 861–879, 2006.
   PubMed Web of Science ®Google Scholar
• Lee CH: Reversing agents for ATP-binding cassette drug transporters. Methods Mol Biol 596, 325–340, 2010.
   PubMedGoogle Scholar
• Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, et al.: Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 116, 4077–4085, 2010.
   PubMed Web of Science ®Google Scholar
• Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5, 219–234, 2006.
   PubMed Web of Science ®Google Scholar
• Polgar O and Bates SE: ABC transporters in the balance: is there a role in multidrug resistance? Biochem Soc Trans 33, 241–245, 2005.
   PubMed Web of Science ®Google Scholar
• Shukla S, Wu CP, and Ambudkar SV: Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol 4, 205–223, 2008.
   PubMed Web of Science ®Google Scholar
• Leonard GD, Polgar O, and Bates SE: ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 3, 1652–1659, 2002.
   PubMedGoogle Scholar
• Molnar J, Engi H, Hohmann J, Molnar P, Deli J, et al.: Reversal of multidrug resitance by natural substances from plants. Curr Top Med Chem 10, 1757–1768, 2010.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2, 48–58, 2002.
   PubMed Web of Science ®Google Scholar
• Gelsomino G, Corsetto PA, Campia I, Montorfano G, Kopecka J, et al.: Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. Mol Cancer 12, 137, 2013.
   PubMed Web of Science ®Google Scholar
• Eckford PD and Sharom FJ: Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry 47, 13686–13698, 2008.
   PubMed Web of Science ®Google Scholar
• Zhang S, Morris ME: Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304, 1258–1267, 2003.
   PubMed Web of Science ®Google Scholar
• Di Pietro A, Conseil G, Perez-Victoria JM, Dayan G, Baubichon-Cortay H, et al.: Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci 59, 307–322, 2002.
   PubMed Web of Science ®Google Scholar
• Boumendjel A, Di Pietro A, Dumontet C, and Barron D: Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev 22, 512–529, 2002.
   PubMed Web of Science ®Google Scholar
• Hooijberg JH, Broxterman HJ, Scheffer GL, Vrasdonk C, Heijn M, et al.: Potent interaction of flavopiridol with MRP1. Br J Cancer 81, 269–276, 1999.
   PubMed Web of Science ®Google Scholar
• van Zanden JJ, Geraets L, Wortelboer HM, van Bladeren PJ, Rietjens IM, et al.: Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells. Biochem Pharmacol 67, 1607–1617, 2004.
   PubMed Web of Science ®Google Scholar
• Wu CP, Calcagno AM, Hladky SB, Ambudkar SV, and Barrand MA: Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J 272, 4725–4740, 2005.
   PubMed Web of Science ®Google Scholar
• Versantvoort CH, Schuurhuis GJ, Pinedo HM, Eekman CA, Kuiper CM, et al.: Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer 68, 939–946, 1993.
   PubMed Web of Science ®Google Scholar
• Lorendeau D, Dury L, Genoux-Bastide E, Lecerf-Schmidt F, Simoes-Pires C, et al.: Collateral sensitivity of resistant MRP1-overexpressing cells to flavonoids and derivatives through GSH efflux. Biochem Pharmacol 90, 235–245, 2014.
   PubMed Web of Science ®Google Scholar
• Lo YL and Wang W: Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro. Chem Biol Interact 205, 188–197, 2013.
   PubMed Web of Science ®Google Scholar
• Joshi G, Hardas S, Sultana R, St Clair DK, Vore M, et al.: Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain. J Neurosci Res 85, 497–503, 2007.
   PubMed Web of Science ®Google Scholar
• Ma H, Zhou H, Li P, Song X, Miao X, et al.: Effect of ST3GAL 4 and FUT 7 on sialyl Lewis X synthesis and multidrug resistance in human acute myeloid leukemia. Biochim Biophys Acta 1842, 1681–1692, 2014.
   Google Scholar
• Kim JH, Chen C, and Tony KongAN: Resveratrol inhibits genistein-induced multi-drug resistance protein 2 (MRP2) expression in HepG2 cells. Arch Biochem Biophys 512, 160–166, 2011.
   PubMed Web of Science ®Google Scholar
• Bobrowska-Hagerstrand M, Wrobel A, Mrowczynska L, Soderstrom T, Shirataki Y, et al.: Flavonoids as inhibitors of MRP1-like efflux activity in human erythrocytes. A structure-activity relationship study. Oncol Res 13, 463–469, 2003.
   PubMed Web of Science ®Google Scholar
• Lania-Pietrzak B, Michalak K, Hendrich AB, Mosiadz D, Grynkiewicz G, et al.: Modulation of MRP1 protein transport by plant, and synthetically modified flavonoids. Life Sci 77, 1879–1891, 2005.
   PubMed Web of Science ®Google Scholar
• Wesolowska O, Hendrich AB, Laniapietrzak B, Wisniewski J, Molnar J, et al.: Perturbation of the lipid phase of a membrane is not involved in the modulation of MRP1 transport activity by flavonoids. Cell Mol Biol Lett 14, 199–221, 2009.
   PubMed Web of Science ®Google Scholar
• Wesolowska O, Wisniewski J, Sroda K, Krawczenko A, Bielawska-Pohl A, et al.: 8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1. Eur J Pharmacol 644, 32–40, 2010.
   PubMed Web of Science ®Google Scholar
• Critchfield JW, Welsh CJ, Phang JM, and Yeh GC: Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol 48, 1437–1445, 1994.
   PubMed Web of Science ®Google Scholar
• Scambia G, Ranelletti FO, Panici PB, De Vincenzo R, Bonanno G, et al.: Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34, 459–464, 1994.
   PubMed Web of Science ®Google Scholar
• Versantvoort CH, Rhodes T, and Twentyman PR: Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds. Br J Cancer 74, 1949–1954, 1996.
   PubMed Web of Science ®Google Scholar
• Shapiro AB and Ling V: Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 53, 587–596, 1997.
   PubMed Web of Science ®Google Scholar
• Bansal T, Jaggi M, Khar RK, and Talegaonkar S: Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 12, 46–78, 2009.
   PubMed Web of Science ®Google Scholar
• Wesolowska O: Interaction of phenothiazines, stilbenes and flavonoids with multidrug resistance-associated transporters, P-glycoprotein and MRP1. Acta Biochim Pol 58, 433–48, 2011.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Kumar A, and Bharti AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23, 363–398, 2003.
   PubMed Web of Science ®Google Scholar
• Limtrakul P, Chearwae W, Shukla S, Phisalphong C, and Ambudkar SV: Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem 296, 85–95, 2007.
   PubMed Web of Science ®Google Scholar
• Sen GS, Mohanty S, Hossain DM, Bhattacharyya S, Banerjee S, et al.: Curcumin enhances the efficacy of chemotherapy by tailoring p65NFkappaB-p300 cross-talk in favor of p53–p300 in breast cancer. J Biol Chem 286, 42232–42247, 2011.
   PubMed Web of Science ®Google Scholar
• Ruiz de Almodovar C, Ruiz-Ruiz C, Munoz-Pinedo C, Robledo G, and Lopez-Rivas A: The differential sensitivity of Bc1–2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1–2 protein levels. Oncogene 20, 7128–7133, 2001.
   PubMed Web of Science ®Google Scholar
• Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, et al.: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271, 12687–12690, 1996.
   PubMed Web of Science ®Google Scholar
• Zauli G and Secchiero P: The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 17, 245–257, 2006.
   PubMed Web of Science ®Google Scholar
• Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, et al.: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673–682, 1995.
   PubMed Web of Science ®Google Scholar
• Park SJ, Wu CH, Choi MR, Najafi F, Emami A, et al.: P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Biochem Pharmacol 72, 293–307, 2006.
   PubMed Web of Science ®Google Scholar
• Shankar S, Ganapathy S, Chen Q, and Srivastava RK: Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 7, 16, 2008.
   Web of Science ®Google Scholar
• Wahl H, Tan L, Griffith K, Choi M, and Liu JR: Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol 105, 104–112, 2007.
   PubMed Web of Science ®Google Scholar
• Ganta S and Amiji M: Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 6, 928–939, 2009.
   PubMed Web of Science ®Google Scholar
• Yan YD, Kim DH, Sung JH, Yong CS, and Choi HG: Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin. Int J Pharm 399, 116–120, 2010.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21, 2895–2900, 2001.
   PubMed Web of Science ®Google Scholar
• Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, et al.: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14, 4491–4499, 2008.
   PubMed Web of Science ®Google Scholar
• Novakovic M, Pesic M, Trifunovic S, Vuckovic I, Todorovic N, et al.: Diarylheptanoids from the bark of black alder inhibit the growth of sensitive and multi-drug resistant non-small cell lung carcinoma cells. Phytochemistry 97, 46–54, 2014.
   PubMed Web of Science ®Google Scholar
• Kim TH, Shin YJ, Won AJ, Lee BM, Choi WS, et al.: Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta 1840, 615–625, 2014.
   Google Scholar
• Kwatra D, Venugopal A, Standing D, Ponnurangam S, Dhar A, et al.: Bitter melon extracts enhance the activity of chemotherapeutic agents through the modulation of multiple drug resistance. J Pharm Sci 102, 4444–4454, 2013.
   PubMed Web of Science ®Google Scholar
• Sun L, Chen W, Qu L, Wu J, and Si J: Icaritin reverses multidrug resistance of HepG2/ADR human hepatoma cells via downregulation of MDR1 and Pglycoprotein expression. Mol Med Rep 8, 1883–1887, 2013.
   PubMed Web of Science ®Google Scholar
• Wei L, Chen P, Chen Y, Shen A, Chen H, et al.: Pien Tze Huang suppresses the stem-like side population in colorectal cancer cells. Mol Med Rep 9, 261–266, 2014.
   PubMed Web of Science ®Google Scholar
• Kemper EM, Cleypool C, Boogerd W, Beijnen JH, and van Tellingen O: The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol 53, 173–178, 2004.
   PubMed Web of Science ®Google Scholar
• Jianga Z, Jina T, Gaoa F, Liua J, Zhongb J, et al.: Effects of Ganoderic acid Me on inhibiting multidrug resistance and inducing apoptosis in multidrug resistant colon cancer cells. Process Biochemistry 46, 1307–1314, 2011.
   Web of Science ®Google Scholar
• Zhu H, Liu Z, Tang L, Liu J, Zhou M, et al.: Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells. Eur J Pharmacol 696, 43–53, 2012.
   PubMed Web of Science ®Google Scholar
• Nabekura T, Yamaki T, Ueno K, Kitagawa S: Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1. Biochem Biophys Res Commun 369, 363–368, 2008.
   Google Scholar
• Yoshida N, Takada T, Yamamura Y, Adachi I, Suzuki H, et al.: Inhibitory effects of terpenoids on multidrug resistance-associated protein 2- and breast cancer resistance protein-mediated transport. Drug Metab Dispos 36, 1206–1211, 2008.
   PubMed Web of Science ®Google Scholar
• Ahmed-Belkacem A, Macalou S, Borrelli F, Capasso R, Fattorusso E, et al.: Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors. J Med Chem 50, 1933–1938, 2007.
   PubMed Web of Science ®Google Scholar
• Imai Y, Tsukahara S, Asada S, and Sugimoto Y: Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64, 4346–4352, 2004.
   PubMed Web of Science ®Google Scholar
• Tamaki H, Satoh H, Hori S, Ohtani H, and Sawada Y: Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids. Drug Metab Pharmacokinet 25, 170–179, 2010.
   PubMed Web of Science ®Google Scholar
• Rabindran SK, Ross DD, Doyle LA, Yang W, and Greenberger LM: Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60, 47–50, 2000.
   PubMed Web of Science ®Google Scholar
• Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, et al.: Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1, 417–425, 2002.
   PubMed Web of Science ®Google Scholar
• Zou L, Harkey MR, and Henderson GL: Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 71, 1579–1589, 2002.
   PubMed Web of Science ®Google Scholar
• Umathe SN, Dixit PV, Kumar V, Bansod KU, and Wanjari MM: Quercetin pretreatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition. Biochem Pharmacol 75, 1670–1676, 2008.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Vallinas M, Molina S, Vicente G, de la Cueva A, Vargas T, et al.: Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells. Pharmacol Res 72, 61–68, 2013.
   PubMed Web of Science ®Google Scholar
• Abraham I, El Sayed K, Chen ZS, and Guo H: Current status on marine products with reversal effect on cancer multidrug resistance. Mar Drugs 10, 2312–2321, 2012.
   PubMed Web of Science ®Google Scholar
• Wei DD, Wang JS, and Kong LY: Reversal effects of components from the fruits of Illicium simonsii on human Adriamycin-resistant MCF-7 and 5-fluorouracil-resistant Bel7402 cells. Phytother Res 26, 562–567, 2012.
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Erozenci A, Smit J, Danesi R, and Peters GJ: Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol 81, 103–122, 2012.
   PubMed Web of Science ®Google Scholar
• Kruser TJ and Wheeler DL: Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 316, 1083–1100, 2010.
   PubMed Web of Science ®Google Scholar
• Song L, Li Y, Li W, Wu S, and Li Z: MiR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). J Cell Biochem 115, 1234–1242, 2014.
   PubMed Web of Science ®Google Scholar
• Tsubaki M, Komai M, Itoh T, Imano M, Sakamoto K, et al.: By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells. Leuk Res 38, 121–130, 2014.
   PubMed Web of Science ®Google Scholar
• Abbasi M, Lavasanifar A, and Uludag H: Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer. Med Res Rev 33, 33–53, 2013.
   PubMed Web of Science ®Google Scholar
• Feng Y, Hu Y, Cen J, Darshika KN, Fang W, et al.: HZ08 inhibits the multi-drug resistance on multiple sites as the substrate of p-glycoprotein. Eur J Pharmacol 712, 53–59, 2013.
   PubMed Web of Science ®Google Scholar
• Ame JC, Spenlehauer C, and de Murcia G: The PARP superfamily. Bioessays 26, 882–893, 2004.
   PubMed Web of Science ®Google Scholar
• Ashworth A: A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26, 3785–3790, 2008.
   PubMed Web of Science ®Google Scholar
• Annunziata CM and O'Shaughnessy J: Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res 16, 4517–4526, 2010.
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245–251, 2010.
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235–244, 2010.
   PubMed Web of Science ®Google Scholar
• Curtin NJ: PARP inhibitors for cancer therapy. Expert Rev Mol Med 7, 1–20, 2005.
   PubMedGoogle Scholar
• Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, et al.: Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 6, 2860–2867, 2000.
   PubMed Web of Science ®Google Scholar
• Clark CC, Weitzel JN, and O'Connor TR: Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther 11, 1948–1958, 2012.
   PubMed Web of Science ®Google Scholar
• Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, et al.: The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol 9, 144–155, 2012.
   PubMed Web of Science ®Google Scholar
• Zhang J, Kan Y, Tian Y, and Wang Z: Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13* cells. Indian J Med Res 137, 527–532, 2013.
   PubMed Web of Science ®Google Scholar
• Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, et al.: Cisplatin resistance associated with PARP hyperactivation. Cancer Res 73, 2271–2280, 2013.
   PubMed Web of Science ®Google Scholar
• Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, et al.: Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol 229, 422–429, 2013.
   PubMed Web of Science ®Google Scholar
• Yan Y, Bjornmalm M, and Caruso F: Particle carriers for combating multidrug-resistant cancer. ACS Nano 7, 9512–9517, 2013.
   PubMed Web of Science ®Google Scholar
• Markman JL, Rekechenetskiy A, Holler E, and Ljubimova JY: Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev 65, 1866–1879, 2013.
   PubMed Web of Science ®Google Scholar
• Wang AZ, Langer R, and Farokhzad OC: Nanoparticle delivery of cancer drugs. Annu Rev Med 63, 185–198, 2012.
   PubMed Web of Science ®Google Scholar
• Torchilin VP: Antinuclear antibodies with nucleosome-restricted specificity for targeted delivery of chemotherapeutic agents. Ther Deliv 1, 257–272, 2010.
   PubMedGoogle Scholar
• Yang T, Choi MK, Cui FD, Lee SJ, Chung SJ, et al.: Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm Res 24, 2402–2411, 2007.
   PubMed Web of Science ®Google Scholar
• Mattheolabakis G, Rigas B, and Constantinides PP: Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (Lond) 7, 1577–1590, 2012.
   PubMed Web of Science ®Google Scholar
• Apte A, Koren E, Koshkaryev A, and Torchilin VP: Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models. Cancer Biol Ther 15, 69–80, 2014.
   PubMed Web of Science ®Google Scholar
• Zhu H, Chen H, Zeng X, Wang Z, Zhang X, et al.: Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance. Biomaterials 35, 2391–2400, 2014.
   PubMed Web of Science ®Google Scholar
• Zeng X, Morgenstern R, and Nystrom AM: Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-Mediated drug resistance. Biomaterials 35, 1227–1239, 2014.
   PubMed Web of Science ®Google Scholar
• Ma X, Zhao Y, and Ng KW: Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery. Chemistry 19, 15593–15603, 2013.
   PubMed Web of Science ®Google Scholar
• Webster DM, Sundaram P, and Byrne ME: Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics. Eur J Pharm Biopharm 84, 1–20, 2013.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Blais MO, Harris G, and Jabbarzadeh E: PLGA-carbon nanotube conjugates for intercellular delivery of caspase-3 into osteosarcoma cells. PLoS One 8, e81947, 2013.
   PubMed Web of Science ®Google Scholar
• Fabbro C, Ali-Boucetta H, Da RosT, Kostarelos K, Bianco A, et al.: Targeting carbon nanotubes against cancer. Chem Commun (Camb) 48, 3911–3926, 2012.
   PubMed Web of Science ®Google Scholar
• Libutti SK, Paciotti GF, Byrnes AA, Alexander HR, Jr., Gannon WE, et al.: Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 16, 6139–6149, 2010.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang Z, Li S, Ye X, Li X, et al.: Synergy effects of herb extracts: Pharmacokinetics and pharmacodynamic basis. Fitoterapia 92C, 133–147, 2013.
   Google Scholar
• Rather MA, Bhat BA, and Qurishi MA: Multicomponent phytotherapeutic approach gaining momentum: Is the “one drug to fit all” model breaking down? Phytomedicine 21, 1–14, 2013.
   PubMed Web of Science ®Google Scholar